Table 3.
Most common treatment-related AEs of any grade (reported in ≥10% of patients in any arm).
| AE, n (%) | Arm B | Arm C | Arm D | ||||
|---|---|---|---|---|---|---|---|
| Atezo + IFNα | Atezo + PEG-IFNα | Atezo + PEG-IFNα + Bev | |||||
| (n = 65) | (n = 6) | (n = 45) | |||||
| Atezo | IFNα | Atezo | PEG-IFNα | Atezo | PEG-IFNα | Bev | |
| Any treatment-related AE | 44 (67.7) | 60 (92.3) | 6 (100) | 6 (100) | 38 (84.4) | 38 (84.4) | 39 (86.7) |
| Fatigue | 18 (27.7) | 25 (38.5) | 2 (33.3) | 2 (33.3) | 23 (51.1) | 25 (55.6) | 16 (35.6) |
| Chills | 12 (18.5) | 27 (41.5) | 0 | 0 | 6 (13.3) | 6 (13.3) | 5 (11.1) |
| Pyrexia | 8 (12.3) | 23 (35.4) | 0 | 1 (16.7) | 7 (15.6) | 8 (17.8) | 5 (11.1) |
| Arthralgia | 11 (16.9) | 9 (13.8) | 0 | 0 | 4 (8.9) | 8 (17.8) | 1 (2.2) |
| Myalgia | 7 (10.8) | 14 (21.5) | 0 | 0 | 6 (13.3) | 4 (8.9) | 2 (4.4) |
| Headache | 4 (6.2) | 6 (9.2) | 1 (16.7) | 1 (16.7) | 5 (11.1) | 5 (11.1) | 5 (11.1) |
| Nausea | 5 (7.7) | 7 (10.8) | 0 | 1 (16.7) | 6 (13.3) | 7 (15.6) | 6 (13.3) |
| Influenza-like illness | 3 (4.6) | 8 (12.3) | 0 | 0 | 5 (11.1) | 9 (20.0) | 4 (8.9) |
| Proteinuria | 1 (1.5) | 1 (1.5) | 0 | 0 | 1 (2.2) | 1 (2.2) | 12 (26.7) |
| Hypertension | 0 | 0 | 0 | 0 | 0 | 1 (2.2) | 10 (22.2) |
| Hypothyroidism | 8 (12.3) | 2 (3.1) | 1 (16.7) | 0 | 5 (11.1) | 1 (2.2) | 0 |
| Cough | 2 (3.1) | 2 (3.1) | 1 (16.7) | 1 (16.7) | 1 (2.2) | 2 (4.4) | 1 (2.2) |
| Epistaxis | 0 | 1 (1.5) | 0 | 0 | 0 | 0 | 5 (11.1) |
| Eyelid ptosis | 0 | 0 | 1 (16.7) | 1 (16.7) | 0 | 0 | 0 |
| Blood creatinine phosphokinase increase | 0 | 0 | 1 (16.7) | 1 (16.7) | 0 | 0 | 0 |
| Transaminase increase | 0 | 0 | 1 (16.7) | 1 (16.7) | 0 | 0 | 0 |
| Decreased appetite | 4 (6.2) | 5 (7.7) | 1 (16.7) | 1 (16.7) | 2 (4.4) | 4 (8.9) | 2 (4.4) |
| Myasthenia gravis | 0 | 0 | 1 (16.7) | 1 (16.7) | 0 | 0 | 0 |
| Acute respiratory failure | 0 | 0 | 1 (16.7) | 1 (16.7) | 0 | 0 | 0 |
| Hyperthyroidism | 0 | 0 | 1 (16.7) | 1 (16.7) | 2 (4.4) | 0 | 0 |
| Vomiting | 3 (4.6) | 4 (6.2) | 1 (16.7) | 1 (16.7) | 0 | 1 (2.2) | 1 (2.2) |
| Muscular weakness | 0 | 1 (1.5) | 1 (16.7) | 1 (16.7) | 1 (2.2) | 1 (2.2) | 1 (2.2) |
| Pneumonia | 0 | 0 | 1 (16.7) | 1 (16.7) | 0 | 0 | 0 |
| Hypoxia | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Respiratory acidosis | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Tumor-associated fever | 0 | 0 | 1 (16.7) | 0 | 0 | 0 | 0 |
| Anemia | 3 (4.6) | 5 (7.7) | 0 | 1 (16.7) | 3 (6.7) | 3 (6.7) | 2 (4.4) |
| Infusion-related reaction | 1 (1.5) | 0 | 0 | 1 (16.7) | 1 (2.2) | 0 | 0 |
AE, adverse event; atezo, atezolizumab; bev; bevacizumab; IFNα, interferon-α; PEG, polyethylene glycol.